A Multicenter, Open-label, Single-sequence Cross-over Study to Assess Safety, Tolerability, and Pharmacokinetics of Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension Switching From an Oral Stable Dose of Selexipag
Phase of Trial: Phase III
Latest Information Update: 14 Jan 2019
At a glance
- Drugs Selexipag (Primary) ; Selexipag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors Actelion Pharmaceuticals
- 31 May 2018 Status changed from active, no longer recruiting to completed.
- 07 May 2018 Planned End Date changed from 13 Aug 2018 to 28 May 2018.
- 07 May 2018 Planned primary completion date changed from 31 Aug 2018 to 28 May 2018.